Literature DB >> 10084423

Pediatric drug formulations: challenges and potential solutions.

M C Nahata.   

Abstract

Lack of pediatric drug formulations for both currently marketed and new drugs continues to be a challenge. Marketing of commercial products, along with pediatric indications, would be the ultimate solution to the lack of pediatric drug formulations. However, until that occurs, funding of research on extemporaneous formulations proposed by scientists should be a high priority. Government, academia, industry, the USPC, and professional associations should collaborate in developing the best policies and an action plan. Infants and children should not be expected to wait for stable extemporaneous formulations of important drugs until an unrealistic goal of having all generic and new drugs available commercially in suitable formulations has been realized.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084423     DOI: 10.1345/aph.18154

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

1.  Changes in availability of paediatric medicines in Australia between 1998 and 2002.

Authors:  Jocelyn Chui; June Tordoff; David Reith
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

2.  Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.

Authors:  Komathi Balakrishnan; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2006-07-26       Impact factor: 4.335

3.  Access to prescribing information for paediatric medicines in the USA: post-modernization.

Authors:  Larissa Young; Francis Lawes; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2008-12-10       Impact factor: 4.335

4.  Chiral stability of an extemporaneously prepared clopidogrel bisulfate oral suspension.

Authors:  Clay R Tynes; Brad Livingston; Hetesh Patel; John J Arnold
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

Review 5.  Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations.

Authors:  Anteneh Belayneh; Ebisa Tadese; Fantahun Molla
Journal:  Int J Gen Med       Date:  2020-11-09

6.  Frequency, nature and determinants of pharmacy compounded medicines in Dutch community pharmacies.

Authors:  Henk Buurma; Peter A de Smet; Olga P van den Hoff; Henrieke Sysling; Michiel Storimans; Antoine C Egberts
Journal:  Pharm World Sci       Date:  2003-12

7.  Trends in accessibility to medicines for children in New Zealand: 1998-2002.

Authors:  Jocelyn Chui; June Tordoff; Julia Kennedy; David Reith
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

8.  The "child size medicines" concept: policy provisions in Uganda.

Authors:  Jasper Ogwal-Okeng; Anthony Mbonye; Freddie Ssengooba; Rebecca Nantanda; Herbert Muyinda; Ebba Holme Hansen; Xavier Nsabagasani
Journal:  J Pharm Policy Pract       Date:  2015-01-31

9.  Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.

Authors:  Hatim S AlKhatib; Sara Jalouqa; Nour Maraqa; Anna Ratka; Eman Elayeh; Suha Al Muhaissen
Journal:  BMC Health Serv Res       Date:  2019-11-08       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.